TY - STD TI - First-Ever CAR. T-cell therapy approved in U.S. Cancer Discov; 2017. https://doi.org/10.1158/2159-8290.CD-NB2017-126. UR - https://doi.org/10.1158/2159-8290.CD-NB2017-126 ID - ref1 ER - TY - STD TI - FDA Approves Second CAR T-cell Therapy. Cancer Discov; 2017. https://doi.org/10.1158/2159-8290.cd-nb2017-155. UR - https://doi.org/10.1158/2159-8290.cd-nb2017-155 ID - ref2 ER - TY - JOUR AU - DeFrancesco, L. PY - 2017 DA - 2017// TI - CAR-T's forge ahead, despite Juno deaths JO - Nat Biotechnol VL - 35 UR - https://doi.org/10.1038/nbt0117-6b DO - 10.1038/nbt0117-6b ID - DeFrancesco2017 ER - TY - JOUR AU - Teachey, D. T. AU - Lacey, S. F. AU - Shaw, P. A. AU - Melenhorst, J. J. AU - Maude, S. L. AU - Frey, N. PY - 2016 DA - 2016// TI - Identification of predictive biomarkers for cytokine release syndrome after Chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia JO - Cancer Discov VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-16-0040 DO - 10.1158/2159-8290.CD-16-0040 ID - Teachey2016 ER - TY - STD TI - Wang Z, Guo Y, Han W. Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. Protein Cell; 2017. https://doi.org/10.1007/s13238-017-0400-z. UR - https://doi.org/10.1007/s13238-017-0400-z ID - ref5 ER - TY - JOUR AU - Dai, H. AU - Wang, Y. AU - Lu, X. AU - Han, W. PY - 2016 DA - 2016// TI - Chimeric antigen receptors modified T-cells for cancer therapy JO - J Natl Cancer Inst VL - 108 UR - https://doi.org/10.1093/jnci/djv439 DO - 10.1093/jnci/djv439 ID - Dai2016 ER - TY - STD TI - Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol; 2017. https://doi.org/10.1038/nrclinonc.2017.128. UR - https://doi.org/10.1038/nrclinonc.2017.128 ID - ref7 ER - TY - STD TI - Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol; 2017. https://doi.org/10.1038/nrclinonc.2017.148. UR - https://doi.org/10.1038/nrclinonc.2017.148 ID - ref8 ER - TY - JOUR AU - Buechner, J. AU - Grupp, S. A. AU - Maude, S. L. AU - Boyer, M. AU - Bittencourt, H. AU - Laetsch, T. W. PY - 2017 DA - 2017// TI - Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): update to the interim analysis JO - Clinical Lymphoma Myeloma Leuk VL - 17 UR - https://doi.org/10.1016/j.clml.2017.07.030 DO - 10.1016/j.clml.2017.07.030 ID - Buechner2017 ER - TY - STD TI - Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med; 2017. https://doi.org/10.1056/NEJMoa1707447. UR - https://doi.org/10.1056/NEJMoa1707447 ID - ref10 ER - TY - JOUR AU - Lee, D. W. AU - Gardner, R. AU - Porter, D. L. AU - Louis, C. U. AU - Ahmed, N. AU - Jensen, M. PY - 2014 DA - 2014// TI - Current concepts in the diagnosis and management of cytokine release syndrome JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-05-552729 DO - 10.1182/blood-2014-05-552729 ID - Lee2014 ER - TY - JOUR AU - Fitzgerald, J. C. AU - Weiss, S. L. AU - Maude, S. L. AU - Barrett, D. M. AU - Lacey, S. F. AU - Melenhorst, J. J. PY - 2017 DA - 2017// TI - Cytokine release syndrome after Chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia JO - Crit Care Med VL - 45 UR - https://doi.org/10.1097/CCM.0000000000002053 DO - 10.1097/CCM.0000000000002053 ID - Fitzgerald2017 ER - TY - STD TI - Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 Chimeric antigen receptor-modified T cell therapy. Blood; 2017. https://doi.org/10.1182/blood-2017-06-793141. UR - https://doi.org/10.1182/blood-2017-06-793141 ID - ref13 ER - TY - JOUR AU - Gust, J. AU - Hay, K. A. AU - Hanafi, L. A. AU - Li, D. AU - Myerson, D. AU - Gonzalez-Cuyar, L. F. PY - 2017 DA - 2017// TI - Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-17-0698 DO - 10.1158/2159-8290.CD-17-0698 ID - Gust2017 ER - TY - STD TI - Obstfeld AE, Frey NV, Mansfield K, Lacey SF, June CH, Porter DL, et al. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy; clinicopathological insights. Blood. 2017; https://doi.org/10.1182/blood-2017-08-802413. ID - ref15 ER - TY - JOUR AU - Park, J. H. AU - Santomasso, B. AU - Riviere, I. AU - Senechal, B. AU - Wang, X. AU - Purdon, T. PY - 2017 DA - 2017// TI - Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL JO - J Clin Oncol VL - 35 ID - Park2017 ER - TY - JOUR AU - Frey, N. PY - 2017 DA - 2017// TI - Cytokine release syndrome: who is at risk and how to treat JO - Best Pract Res Clin Haematol VL - 30 UR - https://doi.org/10.1016/j.beha.2017.09.002 DO - 10.1016/j.beha.2017.09.002 ID - Frey2017 ER - TY - JOUR AU - Schuster, S. J. AU - Bishop, M. R. AU - Tam, C. AU - Waller, E. K. AU - Borchmann, P. AU - McGuirk, J. PY - 2017 DA - 2017// TI - Global pivotal phase 2 trial of the Cd19-targeted therapy Ctl019 in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (Dlbcl)-an interim analysis JO - Hematol Oncol VL - 35 UR - https://doi.org/10.1002/hon.2437_6 DO - 10.1002/hon.2437_6 ID - Schuster2017 ER - TY - JOUR AU - Gardner, R. A. AU - Finney, O. AU - Annesley, C. AU - Brakke, H. AU - Summers, C. AU - Leger, K. PY - 2017 DA - 2017// TI - Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults JO - Blood VL - 129 UR - https://doi.org/10.1182/blood-2016-10-748772 DO - 10.1182/blood-2016-10-748772 ID - Gardner2017 ER - TY - STD TI - Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med; 2017. https://doi.org/10.1056/NEJMoa1708566. UR - https://doi.org/10.1056/NEJMoa1708566 ID - ref20 ER - TY - STD TI - DeAngelo DJ, Ghobadi A, Park JH, Dinner SN, Mannis GN, Lunning MA, et al. 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One National Harbor, MD, USA. 8-12 November 2017 Abstracts. J Immunother Cancer. 2017;5(Suppl 2):P217. ID - ref21 ER - TY - JOUR AU - Abramson, J. S. AU - Palomba, M. L. AU - Gordon, L. I. AU - Lunning, M. A. AU - Arnason, J. E. AU - Wang, M. PY - 2017 DA - 2017// TI - High durable CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort JO - Blood VL - 130 UR - https://doi.org/10.1182/blood-2017-03-771832 DO - 10.1182/blood-2017-03-771832 ID - Abramson2017 ER - TY - STD TI - Hu Y, Wu Z, Yu J, Wang J, Wei G, Wu W, et al. Efficacy of CD19-targeted chimeric antigen receptor T cells in the treatment of relapsed extramedullary B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2017;35:–e14549. ID - ref23 ER - TY - JOUR AU - Xiao, L. AU - Huang, H. AU - Huang, X. AU - Ke, X. AU - Hu, Y. AU - Li, J. PY - 2017 DA - 2017// TI - Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.4_suppl.544 DO - 10.1200/JCO.2017.35.4_suppl.544 ID - Xiao2017 ER - TY - JOUR AU - Wang, Y. AU - Chen, M. AU - Wu, Z. AU - Tong, C. AU - Huang, J. AU - Lv, H. PY - 2017 DA - 2017// TI - CD133-redirected chimeric antigen receptor engineered autologous T-cell treatment in patients with advanced and metastatic malignancies JO - J Clin Oncol VL - 35 ID - Wang2017 ER - TY - STD TI - Yescarta (axicabtagene ciloleucel) suspension for intravenous infusion prescribing information, Kite Pharma, Inc, October 2017. Available at https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm581222.htm. Accessed 7 Nov 2017. UR - https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm581222.htm ID - ref26 ER - TY - STD TI - Kymriah (tisagenlecleucel) suspension for intravenous infusion prescribing information, Novartis Pharmaceuticals Corp; 2017. Available at www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM573941.pdf. Accessed 6 Sept 2017. UR - http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM573941.pdf ID - ref27 ER - TY - JOUR AU - Maude, S. L. AU - Frey, N. AU - Shaw, P. A. AU - Aplenc, R. AU - Barrett, D. M. AU - Bunin, N. J. PY - 2014 DA - 2014// TI - Chimeric antigen receptor T cells for sustained remissions in leukemia JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1407222 DO - 10.1056/NEJMoa1407222 ID - Maude2014 ER - TY - JOUR AU - Davila, M. L. AU - Riviere, I. AU - Wang, X. AU - Bartido, S. AU - Park, J. AU - Curran, K. PY - 2014 DA - 2014// TI - Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia JO - Sci Transl Med VL - 6 UR - https://doi.org/10.1126/scitranslmed.3008226 DO - 10.1126/scitranslmed.3008226 ID - Davila2014 ER - TY - STD TI - Mei H, Jiang H, Wu Y, Guo T, Xia L, Jin R, et al. Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy. Br J Haematol; 2017. https://doi.org/10.1111/bjh.14680. UR - https://doi.org/10.1111/bjh.14680 ID - ref30 ER - TY - JOUR AU - Dai, H. AU - Zhang, W. AU - Li, X. AU - Han, Q. AU - Guo, Y. AU - Zhang, Y. PY - 2015 DA - 2015// TI - Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia JO - Oncoimmunology VL - 4 UR - https://doi.org/10.1080/2162402X.2015.1027469 DO - 10.1080/2162402X.2015.1027469 ID - Dai2015 ER - TY - JOUR AU - Brudno, J. N. AU - Kochenderfer, J. N. PY - 2016 DA - 2016// TI - Toxicities of chimeric antigen receptor T cells: recognition and management JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2016-04-703751 DO - 10.1182/blood-2016-04-703751 ID - Brudno2016 ER - TY - JOUR AU - Ishii, K. AU - Shalabi, H. AU - Yates, B. AU - Delbrook, C. AU - Mackall, C. L. AU - Fry, T. J. PY - 2016 DA - 2016// TI - Tocilizumab-refractory cytokine release syndrome (CRS) triggered by Chimeric antigen receptor (CAR)-Transduced T cells may have distinct cytokine profiles compared to typical CRS JO - Blood VL - 128 ID - Ishii2016 ER - TY - STD TI - Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood; 2017. https://doi.org/10.1182/blood-2017-06-786129. UR - https://doi.org/10.1182/blood-2017-06-786129 ID - ref34 ER - TY - JOUR AU - Frey, N. V. AU - Levine, B. L. AU - Lacey, S. F. AU - Grupp, S. A. AU - Maude, S. L. AU - Schuster, S. J. PY - 2014 DA - 2014// TI - Refractory cytokine release syndrome in recipients of Chimeric antigen receptor (CAR) T cells JO - Blood VL - 124 ID - Frey2014 ER - TY - JOUR AU - Xu, X. J. AU - Tang, Y. M. PY - 2014 DA - 2014// TI - Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells JO - Cancer Lett VL - 343 UR - https://doi.org/10.1016/j.canlet.2013.10.004 DO - 10.1016/j.canlet.2013.10.004 ID - Xu2014 ER - TY - JOUR AU - Zhang, Y. AU - Zhang, W. AU - Dai, H. AU - Wang, Y. AU - Shi, F. AU - Wang, C. PY - 2016 DA - 2016// TI - An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells JO - Sci China Life Sci VL - 59 UR - https://doi.org/10.1007/s11427-016-5035-4 DO - 10.1007/s11427-016-5035-4 ID - Zhang2016 ER - TY - JOUR AU - Wang, C. M. AU - Wu, Z. Q. AU - Wang, Y. AU - Guo, Y. L. AU - Dai, H. R. AU - Wang, X. H. PY - 2017 DA - 2017// TI - Autologous T cells expressing CD30 Chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-1365 DO - 10.1158/1078-0432.CCR-16-1365 ID - Wang2017 ER - TY - JOUR AU - O'Hara, M. H. AU - Stashwick, C. AU - Plesa, G. AU - Tanyi, J. L. PY - 2017 DA - 2017// TI - Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers JO - Immunotherapy VL - 9 UR - https://doi.org/10.2217/imt-2017-0026 DO - 10.2217/imt-2017-0026 ID - O'Hara2017 ER - TY - JOUR AU - Brentjens, R. AU - Yeh, R. AU - Bernal, Y. AU - Riviere, I. AU - Sadelain, M. PY - 2010 DA - 2010// TI - Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial JO - Mol Ther VL - 18 UR - https://doi.org/10.1038/mt.2010.31 DO - 10.1038/mt.2010.31 ID - Brentjens2010 ER - TY - JOUR AU - Cai, B. AU - Guo, M. AU - Wang, Y. AU - Zhang, Y. AU - Yang, J. AU - Guo, Y. PY - 2016 DA - 2016// TI - Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0357-z DO - 10.1186/s13045-016-0357-z ID - Cai2016 ER - TY - STD TI - Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al. T Cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (London Engl). 2015; 385:517-528. ID - ref42 ER - TY - JOUR AU - Porter, D. L. AU - Hwang, W. T. AU - Frey, N. V. AU - Lacey, S. F. AU - Shaw, P. A. AU - Loren, A. W. PY - 2015 DA - 2015// TI - Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia JO - Sci Transl Med VL - 7 UR - https://doi.org/10.1126/scitranslmed.aac5415 DO - 10.1126/scitranslmed.aac5415 ID - Porter2015 ER - TY - JOUR AU - Frey, N. V. AU - Porter, D. L. PY - 2016 DA - 2016// TI - Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia JO - Hematol Am Soc Hematol Educ Program VL - 2016 ID - Frey2016 ER - TY - JOUR AU - Norman, D. J. AU - Chatenoud, L. AU - Cohen, D. AU - Goldman, M. PY - 1993 DA - 1993// TI - Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies JO - Transplant Proc VL - 25 ID - Norman1993 ER - TY - JOUR AU - Winkler, U. AU - Jensen, M. AU - Manzke, O. AU - Schulz, H. AU - Diehl, V. AU - Engert, A. PY - 1999 DA - 1999// TI - Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8) JO - Blood VL - 94 ID - Winkler1999 ER - TY - JOUR AU - Suntharalingam, G. AU - Perry, M. R. AU - Ward, S. AU - Brett, S. J. AU - Castello-Cortes, A. AU - Brunner, M. D. PY - 2006 DA - 2006// TI - Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa063842 DO - 10.1056/NEJMoa063842 ID - Suntharalingam2006 ER - TY - JOUR AU - Wing, M. G. AU - Moreau, T. AU - Greenwood, J. AU - Smith, R. M. AU - Hale, G. AU - Isaacs, J. PY - 1996 DA - 1996// TI - Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells JO - J Clin Invest VL - 98 UR - https://doi.org/10.1172/JCI119110 DO - 10.1172/JCI119110 ID - Wing1996 ER - TY - JOUR AU - Teachey, D. T. AU - Rheingold, S. R. AU - Maude, S. L. AU - Zugmaier, G. AU - Barrett, D. M. AU - Seif, A. E. PY - 2013 DA - 2013// TI - Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2013-02-485623 DO - 10.1182/blood-2013-02-485623 ID - Teachey2013 ER - TY - STD TI - Rotz SJ, Leino D, Szabo S, Mangino JL, Turpin BK, Pressey JG. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer; 2017. https://doi.org/10.1002/pbc.26642. UR - https://doi.org/10.1002/pbc.26642 ID - ref50 ER - TY - JOUR AU - Tisoncik, J. R. AU - Korth, M. J. AU - Simmons, C. P. AU - Farrar, J. AU - Martin, T. R. AU - Katze, M. G. PY - 2012 DA - 2012// TI - Into the eye of the cytokine storm JO - Microbiol Mol Biol Rev VL - 76 UR - https://doi.org/10.1128/MMBR.05015-11 DO - 10.1128/MMBR.05015-11 ID - Tisoncik2012 ER - TY - JOUR AU - Bugelski, P. J. AU - Achuthanandam, R. AU - Capocasale, R. J. AU - Treacy, G. AU - Bouman-Thio, E. PY - 2009 DA - 2009// TI - Monoclonal antibody-induced cytokine-release syndrome JO - Expert Rev Clin Immunol VL - 5 UR - https://doi.org/10.1586/eci.09.31 DO - 10.1586/eci.09.31 ID - Bugelski2009 ER - TY - JOUR AU - Walker, M. AU - Makropoulos, D. AU - Achuthanandam, R. AU - Bugelski, P. J. PY - 2010 DA - 2010// TI - Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome JO - Curr Opin Drug Discov Devel VL - 13 ID - Walker2010 ER - TY - JOUR AU - Opal, S. M. AU - DePalo, V. A. PY - 2000 DA - 2000// TI - Anti-inflammatory cytokines JO - Chest VL - 117 UR - https://doi.org/10.1378/chest.117.4.1162 DO - 10.1378/chest.117.4.1162 ID - Opal2000 ER - TY - JOUR AU - Balkwill, F. R. AU - Burke, F. PY - 1989 DA - 1989// TI - The cytokine network JO - Immunol Today VL - 10 UR - https://doi.org/10.1016/0167-5699(89)90085-6 DO - 10.1016/0167-5699(89)90085-6 ID - Balkwill1989 ER - TY - JOUR AU - Yiu, H. H. AU - Graham, A. L. AU - Stengel, R. F. PY - 2012 DA - 2012// TI - Dynamics of a cytokine storm JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0045027 DO - 10.1371/journal.pone.0045027 ID - Yiu2012 ER - TY - JOUR AU - Harris, D. T. AU - Kranz, D. M. PY - 2016 DA - 2016// TI - Adoptive T cell therapies: a comparison of T cell receptors and Chimeric antigen receptors JO - Trends Pharmacol Sci VL - 37 UR - https://doi.org/10.1016/j.tips.2015.11.004 DO - 10.1016/j.tips.2015.11.004 ID - Harris2016 ER - TY - STD TI - Yang Y, Kohler ME, Chien CD, Sauter CT, Jacoby E, Yan C, et al. TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci Transl Med; 2017. https://doi.org/10.1126/scitranslmed.aag1209. UR - https://doi.org/10.1126/scitranslmed.aag1209 ID - ref58 ER - TY - JOUR AU - Adusumilli, P. S. AU - Cherkassky, L. AU - Villena-Vargas, J. AU - Colovos, C. AU - Servais, E. AU - Plotkin, J. PY - 2014 DA - 2014// TI - Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity JO - Sci Transl Med VL - 6 UR - https://doi.org/10.1126/scitranslmed.3010162 DO - 10.1126/scitranslmed.3010162 ID - Adusumilli2014 ER - TY - JOUR AU - Wu, C. AU - Xue, Y. AU - Wang, P. AU - Lin, L. AU - Liu, Q. AU - Li, N. PY - 2014 DA - 2014// TI - IFN-γ primes macrophage activation by increasing Phosphatase and Tensin homolog via Downregulation of miR-3473b JO - J Immunol VL - 193 UR - https://doi.org/10.4049/jimmunol.1302379 DO - 10.4049/jimmunol.1302379 ID - Wu2014 ER - TY - JOUR AU - Martinez, F. O. AU - Helming, L. AU - Gordon, S. PY - 2009 DA - 2009// TI - Alternative activation of macrophages: an immunologic functional perspective JO - Annu Rev Immunol VL - 27 UR - https://doi.org/10.1146/annurev.immunol.021908.132532 DO - 10.1146/annurev.immunol.021908.132532 ID - Martinez2009 ER - TY - JOUR AU - Prudent, V. AU - Breitbart, W. S. PY - 2017 DA - 2017// TI - Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia JO - Palliat Support Care VL - 15 UR - https://doi.org/10.1017/S147895151600095X DO - 10.1017/S147895151600095X ID - Prudent2017 ER - TY - STD TI - Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med; 2017. https://doi.org/10.1038/nm.4441. UR - https://doi.org/10.1038/nm.4441 ID - ref63 ER - TY - JOUR AU - Hawkes, N. PY - 2016 DA - 2016// TI - Trial of novel leukaemia drug is stopped for second time after two more deaths JO - BMJ VL - 355 UR - https://doi.org/10.1136/bmj.i6376 DO - 10.1136/bmj.i6376 ID - Hawkes2016 ER - TY - JOUR AU - Abbasi, J. AU - Amid, F. D. A. PY - 2017 DA - 2017// TI - Approval filings, another CAR-T therapy patient death JO - JAMA VL - 317 ID - Abbasi2017 ER - TY - JOUR AU - Topp, M. S. AU - Gökbuget, N. AU - Stein, A. S. AU - Zugmaier, G. AU - O'Brien, S. AU - Bargou, R. C. PY - 2015 DA - 2015// TI - Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71170-2 DO - 10.1016/S1470-2045(14)71170-2 ID - Topp2015 ER - TY - JOUR AU - Wu, J. AU - Fu, J. AU - Zhang, M. AU - Liu, D. PY - 2015 DA - 2015// TI - Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0195-4 DO - 10.1186/s13045-015-0195-4 ID - Wu2015 ER - TY - JOUR AU - Fan, G. AU - Wang, Z. AU - Hao, M. AU - Li, J. PY - 2015 DA - 2015// TI - Bispecific antibodies and their applications JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0227-0 DO - 10.1186/s13045-015-0227-0 ID - Fan2015 ER - TY - STD TI - O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med; 2017. https://doi.org/10.1126/scitranslmed.aaa0984. UR - https://doi.org/10.1126/scitranslmed.aaa0984 ID - ref69 ER - TY - JOUR AU - Abramson, J. S. AU - McGree, B. AU - Noyes, S. AU - Plummer, S. AU - Wong, C. AU - Chen, Y. B. PY - 2017 DA - 2017// TI - Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMc1704610 DO - 10.1056/NEJMc1704610 ID - Abramson2017 ER - TY - JOUR AU - Hu, Y. AU - Sun, J. AU - Wu, Z. AU - Yu, J. AU - Cui, Q. AU - Pu, C. PY - 2016 DA - 2016// TI - Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0299-5 DO - 10.1186/s13045-016-0299-5 ID - Hu2016 ER - TY - JOUR AU - Mackall, C. L. AU - Miklos, D. B. PY - 2017 DA - 2017// TI - CNS endothelial cell activation emerges as a driver of CAR T cell-associated neurotoxicity JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-17-1084 DO - 10.1158/2159-8290.CD-17-1084 ID - Mackall2017 ER - TY - JOUR AU - Kometani, H. AU - Kawatani, M. AU - Ohta, G. AU - Okazaki, S. AU - Ogura, K. AU - Yasutomi, M. PY - 2014 DA - 2014// TI - Marked elevation of interleukin-6 in mild encephalopathy with a reversible splenial lesion (MERS) associated with acute focal bacterial nephritis caused by Enterococcus faecalis JO - Brain and Development VL - 36 UR - https://doi.org/10.1016/j.braindev.2013.07.012 DO - 10.1016/j.braindev.2013.07.012 ID - Kometani2014 ER - TY - STD TI - Inman S. JCAR015 Experience Informs Future CAR-T Studies. OncLive; 2017. http://www.onclive.com/web-exclusives/jcar015-experience-informs-future-cart-studies. Accessed 10 Nov 2017. UR - http://www.onclive.com/web-exclusives/jcar015-experience-informs-future-cart-studies ID - ref74 ER - TY - JOUR AU - Turtle, C. J. AU - Hay, K. A. AU - Hanafi, L. A. AU - Li, D. AU - Cherian, S. AU - Chen, X. PY - 2017 DA - 2017// TI - Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific Chimeric antigen receptor-modified T cells after failure of Ibrutinib JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.72.8519 DO - 10.1200/JCO.2017.72.8519 ID - Turtle2017 ER - TY - JOUR AU - Turtle, C. J. AU - Hanafi, L. A. AU - Berger, C. AU - Gooley, T. A. AU - Cherian, S. AU - Hudecek, M. PY - 2016 DA - 2016// TI - CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients JO - J Clin Invest VL - 126 UR - https://doi.org/10.1172/JCI85309 DO - 10.1172/JCI85309 ID - Turtle2016 ER - TY - JOUR AU - Wang, Y. AU - Zhang, W. Y. AU - Han, Q. W. AU - Liu, Y. AU - Dai, H. R. AU - Guo, Y. L. PY - 2014 DA - 2014// TI - Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells JO - Clin Immunol VL - 155 UR - https://doi.org/10.1016/j.clim.2014.10.002 DO - 10.1016/j.clim.2014.10.002 ID - Wang2014 ER - TY - JOUR AU - Rouce, R. H. AU - Heslop, H. E. PY - 2016 DA - 2016// TI - Forecasting cytokine storms with new predictive biomarkers JO - Cancer Discov VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-16-0493 DO - 10.1158/2159-8290.CD-16-0493 ID - Rouce2016 ER - TY - JOUR AU - Zhang, W. -. y. AU - Wang, Y. AU - Guo, Y. -. l. AU - Dai, H. -. r. AU - Yang, Q. -. m. AU - Zhang, Y. -. j. PY - 2016 DA - 2016// TI - Treatment of CD20-directed Chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report JO - Signal Transduct Target Ther VL - 1 UR - https://doi.org/10.1038/sigtrans.2016.2 DO - 10.1038/sigtrans.2016.2 ID - Zhang2016 ER - TY - JOUR AU - Turtle, C. J. AU - Hay, K. A. AU - Gust, J. AU - Hanafi, L. -. A. AU - Li, D. AU - Liles, W. C. PY - 2017 DA - 2017// TI - Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.72.8519 DO - 10.1200/JCO.2017.72.8519 ID - Turtle2017 ER - TY - JOUR AU - Park, J. H. AU - Riviere, I. AU - Wang, X. Y. AU - Purdon, T. AU - Sadelain, M. AU - Brentjens, R. J. PY - 2016 DA - 2016// TI - Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL JO - J Clin Oncol VL - 34 ID - Park2016 ER - TY - JOUR AU - Porter, D. L. AU - Levine, B. L. AU - Kalos, M. AU - Bagg, A. AU - June, C. H. PY - 2011 DA - 2011// TI - Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1103849 DO - 10.1056/NEJMoa1103849 ID - Porter2011 ER - TY - STD TI - Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell; 2017. https://doi.org/10.1007/s13238-017-0440-4. UR - https://doi.org/10.1007/s13238-017-0440-4 ID - ref83 ER - TY - JOUR AU - Turtle, C. J. AU - Hanafi, L. A. AU - Berger, C. AU - Hudecek, M. AU - Pender, B. AU - Robinson, E. PY - 2016 DA - 2016// TI - Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells JO - Sci Transl Med VL - 8 UR - https://doi.org/10.1126/scitranslmed.aaf8621 DO - 10.1126/scitranslmed.aaf8621 ID - Turtle2016 ER - TY - JOUR AU - Xu, Y. AU - Zhang, M. AU - Ramos, C. A. AU - Durett, A. AU - Liu, E. AU - Dakhova, O. PY - 2014 DA - 2014// TI - Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15 JO - Blood VL - 123 UR - https://doi.org/10.1182/blood-2014-01-552174 DO - 10.1182/blood-2014-01-552174 ID - Xu2014 ER - TY - JOUR AU - Hoyos, V. AU - Savoldo, B. AU - Quintarelli, C. AU - Mahendravada, A. AU - Zhang, M. AU - Vera, J. PY - 2010 DA - 2010// TI - Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma|[sol]|leukemia effects and safety JO - Leukemia VL - 24 UR - https://doi.org/10.1038/leu.2010.75 DO - 10.1038/leu.2010.75 ID - Hoyos2010 ER - TY - JOUR AU - Waldmann, T. A. PY - 2014 DA - 2014// TI - Interleukin-15 in the treatment of cancer JO - Expert Rev Clin Immunol VL - 10 UR - https://doi.org/10.1586/1744666X.2014.973856 DO - 10.1586/1744666X.2014.973856 ID - Waldmann2014 ER - TY - JOUR AU - Kochenderfer, J. N. AU - Somerville, R. P. T. AU - Lu, T. AU - Shi, V. AU - Bot, A. AU - Rossi, J. PY - 2017 DA - 2017// TI - Lymphoma remissions caused by anti-CD19 Chimeric antigen receptor T cells are associated with high serum Interleukin-15 levels JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.71.3024 DO - 10.1200/JCO.2016.71.3024 ID - Kochenderfer2017 ER - TY - JOUR AU - Turtle, C. J. AU - Hay, K. A. AU - Juliane, G. AU - Hanafi, L. A. AU - Li, D. AU - Chaney, C. PY - 2016 DA - 2016// TI - Biomarkers of cytokine release syndrome and neurotoxicity after CD19 CAR-T cells and mitigation of toxicity by cell dose JO - Blood VL - 128 ID - Turtle2016 ER - TY - JOUR AU - Gardner, R. AU - Leger, K. J. AU - Annesley, C. E. AU - Summers, C. AU - Rivers, J. AU - Gust, J. PY - 2016 DA - 2016// TI - Decreased rates of severe CRS seen with early intervention strategies for CD19 CAR-T cell toxicity management JO - Blood VL - 128 UR - https://doi.org/10.1182/blood-2016-05-716910 DO - 10.1182/blood-2016-05-716910 ID - Gardner2016 ER - TY - STD TI - Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, et al. Preliminary results of prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with Refractory,Aggressive non-Hodgkin lymphoma (NHL). Blood. 2017;130:–1547. ID - ref91 ER - TY - JOUR AU - Wang, Z. AU - Wu, Z. AU - Liu, Y. AU - Han, W. PY - 2017 DA - 2017// TI - New development in CAR-T cell therapy JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0423-1 DO - 10.1186/s13045-017-0423-1 ID - Wang2017 ER - TY - STD TI - Lichtman EI, Dotti G. Chimeric antigen receptor T-cells for B-cell malignancies. Transl Res; 2017. https://doi.org/10.1016/j.trsl.2017.06.011. UR - https://doi.org/10.1016/j.trsl.2017.06.011 ID - ref93 ER - TY - JOUR AU - Di Stasi, A. AU - Tey, S. K. AU - Dotti, G. AU - Fujita, Y. AU - Kennedy-Nasser, A. AU - Martinez, C. PY - 2011 DA - 2011// TI - Inducible apoptosis as a safety switch for adoptive cell therapy JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1106152 DO - 10.1056/NEJMoa1106152 ID - Di Stasi2011 ER - TY - JOUR AU - Wang, X. AU - Chang, W. C. AU - Wong, C. W. AU - Colcher, D. AU - Sherman, M. AU - Ostberg, J. R. PY - 2011 DA - 2011// TI - A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-02-337360 DO - 10.1182/blood-2011-02-337360 ID - Wang2011 ER - TY - JOUR AU - Philip, B. AU - Kokalaki, E. AU - Mekkaoui, L. AU - Thomas, S. AU - Straathof, K. AU - Flutter, B. PY - 2014 DA - 2014// TI - A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-01-545020 DO - 10.1182/blood-2014-01-545020 ID - Philip2014 ER - TY - STD TI - Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med; 2017. https://doi.org/10.1126/scitranslmed.aaj2013. UR - https://doi.org/10.1126/scitranslmed.aaj2013 ID - ref97 ER -